Frontiers in Cell and Developmental Biology (Sep 2022)

Pathobiological functions and clinical implications of annexin dysregulation in human cancers

  • Llara Prieto-Fernández,
  • Llara Prieto-Fernández,
  • Sofía T. Menéndez,
  • Sofía T. Menéndez,
  • María Otero-Rosales,
  • Irene Montoro-Jiménez,
  • Irene Montoro-Jiménez,
  • Francisco Hermida-Prado,
  • Francisco Hermida-Prado,
  • Juana M. García-Pedrero,
  • Juana M. García-Pedrero,
  • Saúl Álvarez-Teijeiro,
  • Saúl Álvarez-Teijeiro

DOI
https://doi.org/10.3389/fcell.2022.1009908
Journal volume & issue
Vol. 10

Abstract

Read online

Annexins are an extensive superfamily of structurally related calcium- and phospholipid-binding proteins, largely conserved and widely distributed among species. Twelve human annexins have been identified, referred to as Annexin A1-13 (A12 remains as of yet unassigned), whose genes are spread throughout the genome on eight different chromosomes. According to their distinct tissue distribution and subcellular localization, annexins have been functionally implicated in a variety of biological processes relevant to both physiological and pathological conditions. Dysregulation of annexin expression patterns and functions has been revealed as a common feature in multiple cancers, thereby emerging as potential biomarkers and molecular targets for clinical application. Nevertheless, translation of this knowledge to the clinic requires in-depth functional and mechanistic characterization of dysregulated annexins for each individual cancer type, since each protein exhibits varying expression levels and phenotypic specificity depending on the tumor types. This review specifically and thoroughly examines the current knowledge on annexin dysfunctions in carcinogenesis. Hence, available data on expression levels, mechanism of action and pathophysiological effects of Annexin A1-13 among different cancers will be dissected, also further discussing future perspectives for potential applications as biomarkers for early diagnosis, prognosis and molecular-targeted therapies. Special attention is devoted to head and neck cancers (HNC), a complex and heterogeneous group of aggressive malignancies, often lately diagnosed, with high mortality, and scarce therapeutic options.

Keywords